Summary & Overview
CPT 81523: NGS Breast Tumor mRNA Expression Risk Index
Headline: CPT code 81523: NGS-based breast tumor mRNA expression assay that reports risk of distant metastasis
Lead: CPT code 81523 denotes a next-generation sequencing Multianalyte Assay with Algorithmic Analysis (MAAA) performed on FFPE breast tumor tissue to measure mRNA expression of 70 content genes and 31 housekeeping genes and produce an algorithm-derived index related to risk of distant metastasis. This genomic diagnostic has implications for breast cancer prognostication and treatment planning.
Why it matters: Nationwide, adoption of tumor genomic assays that combine molecular profiling with algorithmic risk modeling influences clinical decision-making for adjuvant therapy and impacts laboratory billing patterns and payer coverage policies. CPT code 81523 captures a complex, laboratory-based service that intersects oncology, pathology, and molecular diagnostics.
Payers covered: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare are considered in the analysis as major national payers.
What readers will learn: The publication provides benchmarks for use of CPT code 81523, summarizes payer coverage considerations, outlines typical clinical and laboratory contexts for the service, and presents policy and coding notes relevant to reimbursement and claims submission. It also reviews the test's clinical purpose—estimating risk of distant metastasis using mRNA expression—and the typical laboratory and specimen workflow for an FFPE breast tumor NGS assay.
Data notes: Data not available in the input for detailed payer-specific policy language, utilization statistics, associated taxonomies, ICD-10 diagnoses, and related billing codes.
Billing Code Overview
CPT code 81523 describes a next-generation sequencing (NGS) Multianalyte Assay with Algorithmic Analysis (MAAA) performed on a formalin-fixed paraffin-embedded (FFPE) breast tumor tissue specimen. The test evaluates mRNA gene expression across 70 content genes and 31 housekeeping genes, then applies an algorithm that incorporates the molecular results and patient data to generate an index estimating the risk of breast cancer distant metastasis.
Service type: Laboratory molecular diagnostic test (NGS-based gene expression assay, MAAA)
Typical site of service: Clinical laboratory or reference diagnostic laboratory receiving FFPE breast tumor specimens
Clinical & Coding Specifications
Clinical Context
A 58‑year‑old woman with newly diagnosed, estrogen receptor–positive invasive breast carcinoma undergoes lumpectomy. Formalin–fixed paraffin‑embedded (FFPE) tumor blocks are sent to a reference laboratory for a multianalyte assay with algorithmic analysis that quantifies mRNA expression of 70 content genes and 31 housekeeping genes to generate a risk index for distant metastasis (CPT 81523). Specimen handling includes pathology confirmation of tumor cellularity and tumor block selection. The laboratory performs next‑generation sequencing (NGS)–based expression profiling, integrates clinical variables (age, tumor size, nodal status, and others per the assay algorithm), and reports a composite risk score used by the oncology care team to inform adjuvant systemic therapy planning. Typical site of service is an outpatient pathology laboratory or centralized molecular diagnostics reference lab receiving FFPE surgical pathology specimens; sample collection occurs at an acute care hospital, ambulatory surgery center, or outpatient oncology clinic prior to or after surgical resection. The clinical workflow: surgical pathology prepares and certifies the FFPE tissue, requests and documents the molecular test in the medical record, ships the block or unstained slides to the reference lab, the lab performs RNA extraction, NGS assay and algorithmic analysis, issues a report, and the treating oncologist reviews results during adjuvant therapy decision‑making.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|